stockrow
Friday 6 November 2026
Export ANIP’s income statement to Excel — free account
ANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024.
- Revenue
- +27.6%
- EPS
- +29.4%
- Free cash flow
- +85.5%
- Total debt
- −96.2%
Quarter to September 2026, against a year earlier
67.14
2.48
−3.56%
Follow ANIP
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
14.03 | 17.14 | 18.71 | 22.55 |
+8 more quarters Free account |
P/S ratio |
1.48 | 1.79 | 1.74 | 1.79 | |
P/FCF ratio |
7.71 | 10.46 | 8.80 | 10.49 | |
P/Operating CF |
18.39 | 30.91 | 27.55 | 52.13 | |
P/B ratio |
2.42 | 2.93 | 2.86 | 2.93 | |
Price to Tangible BV |
10.89 | 20.64 | 49.24 | 0.00 | |
EV/Sales |
1.65 | 2.03 | 2.05 | 2.16 | |
EV/EBITDA |
7.27 | 8.41 | 8.89 | 9.41 | |
EV/Operating CF |
7.49 | 10.48 | 9.09 | 10.29 | |
EV/FCF |
8.59 | 11.86 | 10.37 | 12.63 | |
Quick Ratio |
2.25 | 2.29 | 2.43 | 2.07 | |
Current Ratio |
2.75 | 2.91 | 3.12 | 2.71 | |
Net Debt/EBITDA |
0.00 | 3.90 | 4.81 | 5.62 | |
Debt/Assets |
1.49% | 40.86% | 43.16% | 42.84% | |
Debt/Equity |
0.04 | 1.02 | 1.09 | 1.14 | |
Asset Turnover |
0.70 | 0.69 | 0.68 | 0.65 | |
Operating CF/Net income |
2.38 | 2.29 | 1.98 | 1.10 | |
Capex/Depreciation |
0.00 | (0.16) | (0.54) | (0.06) | |
Interest Coverage |
17.14 | 11.13 | 10.32 | 7.88 | |
Research and Development Expense of Revenue |
4.47% | 5.54% | 4.46% | 4.96% | |
Selling, General and Administrative Expense of Revenue |
32.62% | 34.45% | 31.02% | 33.51% | |
Intangible Assets out of Total Assets |
0.32 | 0.34 | 0.37 | 0.38 | |
Share Based Compensation of Revenue |
4.00% | 4.29% | 4.29% | 3.95% | |
Graham Net Nets |
(0.02) | (0.04) | (0.07) | (0.09) | |
Graham Number |
59.17 | 55.39 | 49.86 | 46.08 | |
Earnings Yield |
7.13% | 5.83% | 5.34% | 4.43% | |
Free Cash Flow Yield |
12.97% | 9.56% | 11.37% | 9.53% | |
Revenue per Share |
13.71 | 12.57 | 11.35 | 12.32 | |
Operating CF per Share |
3.95 | 2.68 | 2.79 | 1.51 | |
Capex per Share |
(0.64) | (0.14) | (0.54) | (0.07) | |
Free Cash Flow per Share |
3.31 | 2.53 | 2.25 | 1.44 | |
Cash per Share |
20.57 | 17.77 | 15.59 | 14.70 | |
Shareholders Equity per Share |
30.04 | 28.23 | 26.89 | 26.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
30.04 | 28.23 | 26.89 | 26.96 | |
Free Cash Flow |
70.28 | 53.62 | 47.05 | 28.96 | |
Working Capital |
574.10 | 541.78 | 507.57 | 475.01 | |
Capital Expenditures |
(13.50) | (3.05) | (11.32) | (1.40) | |
Net Current Asset Value |
(27.73) | (71.47) | (112.59) | (146.54) | |
EV/EBIT |
10.31 | 13.21 | 15.32 | 17.15 | |
Capex to Sales |
0.05 | 0.01 | 0.05 | 0.01 | |
Price to Operating Income |
9.26 | 11.65 | 12.99 | 14.25 | |
| Other line items | |||||
Average Receivables |
278.53 | 250.06 | 237.88 | 251.40 | |
Average Payables |
72.11 | 64.20 | 61.38 | 54.12 | |
Average Inventory |
141.44 | 140.73 | 140.44 | 139.92 | |
Average Assets |
1,487.91 | 1,418.56 | 1,357.20 | 1,362.42 | |
Average Common Equity |
571.47 | 516.98 | 490.46 | 472.20 |
Columns are period end dates · fundamentals updated 5 Nov 2026